| Symbol | QCLS |
|---|---|
| Name | Q/C TECHNOLOGIES, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Address | 1185 AVENUE OF THE AMERICAS, NEW YORK, NY 10036 |
| Telephone | 856-848-8698 |
| Fax | — |
| — | |
| Website | https://www.tnfpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001321834 |
| Description | TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), is a clinical stage pharmaceutical company committed to extending healthy lifespan. We are focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-alpha, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. Our second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. Additional info from NASDAQ: |
(99% Neutral) Q/C TECHNOLOGIES, INC. (QCLS) Announces Business Combination
Read moreQ/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference Initiative
Read moreQ/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference Initiative
Read moreDirector Voss Chelsea Sierra 🟢 acquired 1.8K shares of Q/C TECHNOLOGIES, INC. (QCLS) at $3.15 Transaction Date: Mar 30, 2026 | Filing ID: 023217
Read moreNew Form 10-K/A - Q/C TECHNOLOGIES, INC. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001493152-26-019663 <b>Size:</b> 1 MB
Read moreDirector Voss Chelsea Sierra 🟢 acquired 50.0K shares (1 derivative) of Q/C TECHNOLOGIES, INC. (QCLS) at $5.00 Transaction Date: Apr 13, 2026 | Filing ID: 016913
Read moreDirector Friscia Stephen 🟢 acquired 50.0K shares (1 derivative) of Q/C TECHNOLOGIES, INC. (QCLS) at $5.00 Transaction Date: Apr 13, 2026 | Filing ID: 016910
Read moreDirector Glass Mitchell 🟢 acquired 50.0K shares (1 derivative) of Q/C TECHNOLOGIES, INC. (QCLS) at $5.00 Transaction Date: Apr 13, 2026 | Filing ID: 016911
Read moreDirector White Billy Joe 🟢 acquired 50.0K shares (1 derivative) of Q/C TECHNOLOGIES, INC. (QCLS) at $5.00 Transaction Date: Apr 13, 2026 | Filing ID: 016914
Read moreDirector Silverman Joshua 🟢 acquired 262.2K shares (1 derivative) of Q/C TECHNOLOGIES, INC. (QCLS) at $5.00 Transaction Date: Apr 13, 2026 | Filing ID: 016912
Read more